Free Whitepaper Download

Many advancements are ongoing in science and technology, and advanced medicinal products are essential for the treatment and prevention of diseases. Gene and cell therapy, as well as immunotherapy products, belong to the advanced medicinal products category, and a wide variety of product platforms involve new technologies in development, production and control. Rapid expansion of the gene and cell therapy pipeline created constraints to accessing contract capacities around the globe. Innovation in gene and cell therapy expanded many drug development pipelines, and startups that are lacking internal production capacities heavily rely on contract manufacturing organization (CDMO).
Download this whitepaper to learn more.